MX2021004022A - Modificacion genetica de enzimas dnasas para elaboracion y terapia. - Google Patents

Modificacion genetica de enzimas dnasas para elaboracion y terapia.

Info

Publication number
MX2021004022A
MX2021004022A MX2021004022A MX2021004022A MX2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A
Authority
MX
Mexico
Prior art keywords
dnasa1
type
therapy
engineering
manufacturing
Prior art date
Application number
MX2021004022A
Other languages
English (en)
Spanish (es)
Inventor
Tobias A Fuchs
R Abdul Hakkim
Original Assignee
Neutrolis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrolis Inc filed Critical Neutrolis Inc
Publication of MX2021004022A publication Critical patent/MX2021004022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
MX2021004022A 2018-10-08 2019-10-08 Modificacion genetica de enzimas dnasas para elaboracion y terapia. MX2021004022A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862742682P 2018-10-08 2018-10-08
US201862775563P 2018-12-05 2018-12-05
US201862779104P 2018-12-13 2018-12-13
US201962808601P 2019-02-21 2019-02-21
US201962846904P 2019-05-13 2019-05-13
PCT/US2019/055178 WO2020076817A1 (en) 2018-10-08 2019-10-08 Engineering of dnase enzymes for manufacturing and therapy

Publications (1)

Publication Number Publication Date
MX2021004022A true MX2021004022A (es) 2021-09-10

Family

ID=70164727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004022A MX2021004022A (es) 2018-10-08 2019-10-08 Modificacion genetica de enzimas dnasas para elaboracion y terapia.

Country Status (12)

Country Link
US (5) US10988746B2 (enExample)
EP (1) EP3864147A4 (enExample)
JP (3) JP2022504400A (enExample)
KR (1) KR20210072790A (enExample)
CN (1) CN112996911A (enExample)
AU (2) AU2019358915B2 (enExample)
BR (1) BR112021006737A2 (enExample)
CA (1) CA3115766A1 (enExample)
IL (2) IL325846A (enExample)
MX (1) MX2021004022A (enExample)
SG (1) SG11202103426XA (enExample)
WO (1) WO2020076817A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造
US11352613B2 (en) * 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
US20230072226A1 (en) * 2020-02-20 2023-03-09 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
CA3181572A1 (en) * 2020-06-08 2021-12-16 Paul STABACH Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
KR20240004247A (ko) * 2021-02-17 2024-01-11 뉴트롤리스 인코포레이티드 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2
WO2022246139A1 (en) * 2021-05-21 2022-11-24 Genkin Dmitry Dmitrievich Immunomodulation of tumor microenvironment
EP4448743A4 (en) * 2021-12-15 2026-01-14 Univ Texas Tech System IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3
US20250179451A1 (en) * 2022-02-23 2025-06-05 Neutrolis, Inc. Dnase enzymes engineered for improved stability
EP4788836A1 (en) * 2023-10-06 2026-08-12 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 上海交通大学医学院 一种减少线粒体dna泄露的方法
CN120424194A (zh) * 2025-04-30 2025-08-05 苏州泓迅生物科技股份有限公司 一种重组人源纤连蛋白的制备方法及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003230566A1 (en) * 2002-02-26 2003-09-09 Southern Illinois University Therapeutic regulation of deoxyribonuclease-1-like-3 activity
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
DK2086642T3 (da) 2006-10-18 2014-09-29 Periness Ltd Dnase til behandling af subfertilitet hos mænd
EP2076592B1 (en) 2006-10-23 2017-04-12 Medical Research Council Polymerase
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
HUE041426T2 (hu) * 2009-11-02 2019-05-28 Univ Washington Terápiás nukleáz-készítmények és eljárások
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US9644197B2 (en) * 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity
US9198957B2 (en) 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
AU2012222833B2 (en) * 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
CA2834626A1 (en) * 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
US8883735B2 (en) * 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
CA2858983C (en) 2011-12-12 2020-06-09 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
SI3063275T1 (sl) * 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
JP2017527618A (ja) 2014-09-08 2017-09-21 ゴッサム バイオファーマシューティカルズ，インコーポレイティド 肺サルコイドーシスの治療方法
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
CN110199015A (zh) 2016-09-30 2019-09-03 波赛达治疗公司 修饰干细胞记忆t细胞、其制造方法与使用方法
US20190350178A1 (en) * 2017-01-20 2019-11-21 Universitätsklinikum Hamburg-Eppendorf Animal model for drug development
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
UA129696C2 (uk) * 2017-08-18 2025-07-09 Ньютроліс Інк. СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造
US20220025343A1 (en) * 2019-02-04 2022-01-27 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
KR20240004247A (ko) * 2021-02-17 2024-01-11 뉴트롤리스 인코포레이티드 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2
AU2023382621A1 (en) * 2022-11-14 2025-06-05 Neutrolis, Inc. Dnase 1-like 3 engineered for improved expression and use in therapy

Also Published As

Publication number Publication date
IL325846A (en) 2026-03-01
KR20210072790A (ko) 2021-06-17
IL282058B2 (en) 2026-06-01
WO2020076817A1 (en) 2020-04-16
US20200115690A1 (en) 2020-04-16
EP3864147A1 (en) 2021-08-18
IL282058A (en) 2021-05-31
CA3115766A1 (en) 2020-04-16
EP3864147A4 (en) 2022-07-06
JP2022504400A (ja) 2022-01-13
AU2019358915B2 (en) 2025-09-18
JP2024160327A (ja) 2024-11-13
US20210207114A1 (en) 2021-07-08
JP7818850B2 (ja) 2026-02-24
AU2019358915A1 (en) 2021-05-20
US20240191218A1 (en) 2024-06-13
SG11202103426XA (en) 2021-05-28
US10988746B2 (en) 2021-04-27
US11578314B2 (en) 2023-02-14
AU2025283522B2 (en) 2026-03-19
AU2025283522A1 (en) 2026-01-15
CN112996911A (zh) 2021-06-18
IL282058B1 (en) 2026-02-01
US20260152732A1 (en) 2026-06-04
US11840712B2 (en) 2023-12-12
US20220162575A1 (en) 2022-05-26
US12565642B2 (en) 2026-03-03
BR112021006737A2 (pt) 2021-07-13
JP2026082949A (ja) 2026-05-19

Similar Documents

Publication Publication Date Title
MX2020001913A (es) Enzimas dnasa modificadas y uso en terapia.
IL280566A (en) Systems and methods for affecting cardiac contractility and/or relaxation
DOP2019000215A (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
MX2019004241A (es) Composiciones y anticuerpos anti-gen 3 de activacion de linfocitos (lag-3).
EP3618609C0 (en) PLANT TREATMENT SYSTEMS AND METHODS
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
EA201791922A1 (ru) Композиции и способы для борьбы с насекомыми-вредителями
MX385674B (es) Composiciones para modular la expresion de c9orf72.
EP3920974A4 (en) Myosin 15 promoters and uses thereof
EP3423437A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
FR3033494B1 (fr) Endoprothese tissulaire et procede pour sa realisation
EP3805223A4 (en) 2,3-DIHYDRO-1H-PYRROLIZIN-7-FORMAMIDE DERIVATIVE AND USE OF IT
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
DE112020005715T8 (de) Aktuator oder Aufhängung
EA201990864A1 (ru) Конструкции для экспрессии фратаксина
EP3670529A4 (en) ACYLATED OXYNTOMODULIN PEPTIDE ANALOG
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
EP3837370A4 (en) ENZYMATIC COMPOSITIONS FOR CLEAVING CARBOHYDRATE ANTIGENS, METHOD, USES, DEVICES AND SYSTEMS ASSOCIATED THEREOF
MX2018015720A (es) Planta transgenica que tiene resistencia a herbicidas.
MX388393B (es) Plantas de tomate que permiten el establecimiento de los acaros.
MX2021013609A (es) Materiales y métodos para tratar la degeneración macular relacionada con la edad.
MX2019008787A (es) Sal de etano-sulfonato del derivado de quinolina.
UY37979A (es) Sistema de cosecha subacuática mejorado
IL271287A (en) Eye tracking systems and methods